Physician profile
Clifford E Coile
NPI 1881073062
$5,731.90
in general payments reported to CMS, 2019-2025
24 companies · $2,278 in 2025
The $2,278 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $156 · 2021: $422 · 2022: $336 · 2023: $1,187 · 2024: $913 · 2025: $2,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,638 · Travel and Lodging: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.22 |
| Travel and Lodging | $1,739.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,155.39 | 2022-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $428.91 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $416.83 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.10 | 2019-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $369.75 | 2020-2025 | Uptravi, Opsumit |
| Abbvie INC. | $273.90 | 2021-2025 | Teflaro, Avycaz |
| Genzyme Corporation | $260.60 | 2024-2025 | |
| Pfizer INC. | $219.01 | 2019-2021 | |
| Astellas Pharma US INC | $187.62 | 2019-2024 | Cresemba |
| United Therapeutics Corporation | $175.05 | 2019-2024 | |
| Viatris Specialty LLC | $133.63 | 2025 | Yupelri |
| Ethicon INC. | $133.16 | 2021 | |
| Inspire Medical Systems, INC. | $121.07 | 2025 | Inspire |
| Livanova USA, INC. | $117.32 | 2022 | |
| Mallinckrodt Enterprises LLC | $79.14 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $61.99 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $41.41 | 2020-2024 | Winrevair |
| Novartis Pharmaceuticals Corporation | $29.23 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $23.64 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2021 | |
| Tempus Ai, INC | $22.46 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.88 | 2021 | |
| Insmed, INC. | $18.23 | 2025 | Arikayce |
| Vapotherm INC | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Coile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.